Free Trial

JATT Acquisition (JATT) Competitors

JATT Acquisition logo
$1.13 +0.01 (+0.89%)
As of 07/3/2025

JATT vs. ANEB, PLRX, ZURA, ONCY, GNTA, QNCX, INCR, ABOS, PYXS, and IMUX

Should you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Anebulo Pharmaceuticals (ANEB), Pliant Therapeutics (PLRX), Zura Bio (ZURA), Oncolytics Biotech (ONCY), Genenta Science (GNTA), Quince Therapeutics (QNCX), InterCure (INCR), Acumen Pharmaceuticals (ABOS), Pyxis Oncology (PYXS), and Immunic (IMUX). These companies are all part of the "pharmaceutical products" industry.

JATT Acquisition vs. Its Competitors

JATT Acquisition (NYSE:JATT) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

JATT Acquisition's return on equity of -49.58% beat Anebulo Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
JATT AcquisitionN/A -49.58% 2.84%
Anebulo Pharmaceuticals N/A -90.11%-84.53%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JATT AcquisitionN/AN/A$6.85MN/AN/A
Anebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-6.33

Anebulo Pharmaceuticals has a consensus price target of $5.50, indicating a potential upside of 234.35%. Given Anebulo Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Anebulo Pharmaceuticals is more favorable than JATT Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
JATT Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Anebulo Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, JATT Acquisition's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
JATT Acquisition Neutral
Anebulo Pharmaceuticals Neutral

Summary

JATT Acquisition and Anebulo Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

Get JATT Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JATT vs. The Competition

MetricJATT AcquisitionBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$19.49M$205.72M$5.53B$20.71B
Dividend YieldN/AN/A5.24%3.72%
P/E RatioN/AN/A19.3125.95
Price / SalesN/A242.79424.5938.53
Price / Cash27.0822.4426.2118.22
Price / Book-2.135.557.924.59
Net Income$6.85M-$96.61M$3.17B$982.91M
7 Day Performance7.62%-1.69%2.18%1.73%
1 Month Performance-10.32%-2.54%1.25%4.26%
1 Year Performance-67.71%11.05%33.90%14.35%

JATT Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JATT
JATT Acquisition
N/A$1.13
+0.9%
N/A-67.7%$19.49MN/A0.003Gap Up
High Trading Volume
ANEB
Anebulo Pharmaceuticals
2.1916 of 5 stars
$1.81
+3.4%
$5.50
+203.9%
-34.2%$71.90MN/A-6.964High Trading Volume
PLRX
Pliant Therapeutics
3.9483 of 5 stars
$1.20
+2.6%
$13.31
+1,009.4%
-88.2%$71.82M$1.58M-0.3390Gap Up
ZURA
Zura Bio
3.4826 of 5 stars
$1.12
+6.7%
$14.33
+1,179.8%
-67.5%$71.79MN/A-1.603Positive News
Gap Up
ONCY
Oncolytics Biotech
1.6628 of 5 stars
$0.79
+5.0%
$4.33
+450.3%
-12.5%$70.71MN/A-2.7230Gap Down
High Trading Volume
GNTA
Genenta Science
1.8478 of 5 stars
$3.87
+1.3%
$25.00
+546.0%
+25.1%$69.87MN/A0.007Gap Up
QNCX
Quince Therapeutics
2.8764 of 5 stars
$1.60
+5.3%
$8.00
+400.0%
+120.1%$69.11MN/A-1.1560
INCR
InterCure
N/A$1.48
flat
N/A-35.4%$67.45M$64.55M0.00350
ABOS
Acumen Pharmaceuticals
1.2378 of 5 stars
$1.13
+1.8%
$6.33
+460.5%
-49.6%$67.24MN/A-0.5820Positive News
PYXS
Pyxis Oncology
1.2081 of 5 stars
$1.20
+11.1%
$9.00
+650.0%
-61.6%$66.90M$16.15M-0.7560
IMUX
Immunic
2.9282 of 5 stars
$0.71
+3.3%
$11.60
+1,526.9%
-32.5%$66.15MN/A-0.5870Positive News

Related Companies and Tools


This page (NYSE:JATT) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners